Public Health
UK to launch first human challenge trial for COVID-19
The U.K. is funding a $44 million human challenge trial for COVID-19 during which healthy volunteers will be deliberately exposed to the coronavirus.
A deadly virus emerged in South Africa in 2008. Then it vanished.
A deadly new virus killed a South African safari agent and three others, then disappeared without a trace. What can we learn from a unique outbreak?
Patients report sudden hearing loss from COVID-19
Patients are experiencing sudden hearing loss from COVID-19, but if caught early enough, doctors can prevent the problem from becoming permanent.
The coronavirus can survive on surfaces for 28 days
The coronavirus can survive on surfaces, including money, for up to 28 days. But does that change what you need to do to avoid catching COVID-19?
Post-COVID-19 clinics offer hope to coronavirus survivors
Post-COVID-19 clinics are helping coronavirus survivors cope with lingering symptoms while helping researchers better understand the disease.
Comparing COVID-19 vaccines just got way easier
A newly formed network of labs will make it easier to compare COVID-19 vaccines by testing them all in exactly the same way, using the exact same supplies.
Pain relief from coronavirus may be helping it spread
Rather than feeling sick, some people may be getting pain relief from coronavirus — a discovery that could impact both the pandemic and the opioid epidemic.
A new molecule may take the edge off vaccines — and make them perform better
Adjuvants create a better vaccine immune response, but they also cause inflammation. A peptide may help curb their side effects while improving protection.
Coronavirus nasal spray vaccine nears human trials
A nasal spray vaccine for COVID-19 that contains a live coronavirus genetically engineered to replicate more slowly is nearing human trials.
Johnson & Johnson’s COVID-19 vaccine reaches final trial stage
Johnson & Johnson’s COVID-19 vaccine isn’t the first to reach the final human trial stage, but it may have several advantages over its predecessors.